"Combining the short procedure times of cryoablation with the real-time imaging capabilities of the KODEX-EPD system, we have been able to further improve our efficient lab workflow" said Professor Lukas Dekker, Electrophysiologist at Catharina Hospital in Eindhoven, the Netherlands. "Moreover, fluoroless imaging with the KODEX-EPD system may reduce the dependency on fluoroscopy and pre-procedural CTs and thus help to reduce X-ray exposure to patients and staff, which is important to us."
The KODEX-EPD cardiac imaging and mapping system is commercially available in the US, Europe, and China. It is part of Philips' unique portfolio of systems, smart devices, software and services in image-guided therapy, which combine to provide healthcare providers with sophisticated, procedure-oriented solutions.
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries.
Back to HCB News
